Introduction {#s0005}
============

Preoperative neoadjuvant chemotherapy (NAC) has played an increasingly significant role in comprehensive care for locally advanced breast cancers \[[@bb0005]\]. The primary purposes of NAC are to downstage breast cancers and improve the possibility of breast-conserving therapy in most breast cancers \[[@bb0010], [@bb0015], [@bb0020]\]. After preoperative chemotherapy, breast tumors shrink to different extents and show various regression patterns, including pathologic complete response (pCR), unifocal shrinkage, multiple residual foci, main residual disease with satellite foci, stable disease (SD) and progressive disease (PD) \[[@bb0025], [@bb0030], [@bb0035], [@bb0040]\]. Among these patterns, unifocal residual disease and pCR favor the adoption of breast-conserving surgery (BCS). Patients with multiple residual foci, SD and PD are, however, more prone to undergoing mastectomy after completing NAC.

The higher local recurrence rate in NAC than in adjuvant chemotherapy has caused breast cancer specialists to take caution. In a recent meta-analysis, the 15-year local recurrence rate in patients receiving NAC was found to be 5.5% higher than that in patients receiving chemotherapy (21.4% vs 15.9%, *p* = 0.0001) \[[@bb0045]\]. An increase in the BCS rate was speculated to be responsible for this finding since patients with favorable responses to NAC may have successfully changed their original intended surgical plan from mastectomy to BCS. Though the higher IBTR did not cause a significant difference in overall survival, it brought an extra operation and might cause mental stress to patients. A previous study from the University of Pittsburgh determined that multifocal regression independently predicts IBTR \[[@bb0030]\]. Tumor regression patterns were divided into 2 types: pCR plus unifocal regression and multifocal regression. Compared to that in the pCR group, the hazard ratio of tumor recurrence reached 11.2 in the diffuse multifocal regression group. Meanwhile, 9.5% of the patients were recruited for a second operation as a result of the positive margins in their first attempted breast-conserving surgery.

Because satellite/microfoci remain after neoadjuvant chemotherapy, the negative margins in BCS may not be as safe in cancers with multifocal regression. In patients with poor response to NAC, including PD and SD, BCS is obviously not a preferred option. Nakamura \[[@bb0050]\] categorized tumor regression patterns into concentric regression and dendritic regression and determined that nonconcentric regression necessitated careful evaluation for BCS. In this study, tumor regression patterns are categorized into 2 types based on clinical interest. Type 1 regression contains pCR and unifocal regression, for which BCS is the more favored surgical plan. Type 2 regression is composed of multiple residual foci, main residual disease with satellite foci, stable disease (SD) and progressive disease (PD), which are appropriate candidates for mastectomy. In addition to patients\' willingness and contraindications to radiation therapy \[[@bb0055]\], the tumor regression pattern is crucial for determining whether BCS is feasible for an individual patient. Accordingly, the early prediction of the tumor regression pattern is of great value and needs to be studied. The baseline prediction of tumor regression patterns identifies BCS candidates at an early phase. This enables the early modification of treatment strategies for those predicted to have a type 2 regression with great possibility after NAC. In specific molecular subtypes, e.g., TNBC, a more vigorous platinum-based chemotherapy may be adopted in non-BCS candidates to obtain a better chemotherapy response \[[@bb0060]\].

Radiomics has become a novel tool for noninvasively obtaining anatomical tumor information by extracting and analyzing quantitative imaging features \[[@bb0065]\]. Dedicated MRI imaging assists oncologists in providing higher quality medical services, including more precise diagnoses \[[@bb0070],[@bb0075]\], improved predictions of lymph node metastasis \[[@bb0080]\] and more accurate treatment response assessments \[[@bb0085],[@bb0090]\]. Previously, Liu \[[@bb0095]\] and Xiong \[[@bb0100]\] explored the possibility of multiparametric MRI in predicting the treatment response after NAC, focusing on pCR or Miller--Payne grade. Few studies have concentrated on predicting tumor regression patterns that are closely related to surgical options. In this original article, we tried to reveal the correlations between a radiomic signature plus clinicopathological factors and tumor regression patterns.

Material and methods {#s0010}
====================

Patients and factors {#s0015}
--------------------

We retrospectively enrolled 144 patients with stage II-III breast cancers who received NAC and underwent surgery in Guangdong Provincial People\'s Hospital between February 2016 and June 2019. The criteria for patient inclusion were as follows: 1) biopsy-confirmed invasive breast cancer with no distant metastatic disease; 2) no missing baseline clinicopathological factors; 3) MRI examinations in our center prior to biopsy; and 4) definitive surgery following standard preoperative chemotherapy. The exclusion criteria were as follows: 1) missing baseline characteristics; 2) no available MR images or only poor-quality images; 3) patients underwent final surgery at another cancer center and pathologic results were unavailable; and 4) patients did not complete the planned cycles of NAC regimen or had nonstandard NAC treatment (e.g., trastuzumab was not included in the presurgical chemotherapy). We randomly allocated 7/10 of eligible patients to primary cohort and the remaining to validation cohort in a 7:3 ratio.

In this retrospective study, each enrolled patient underwent the planned standard chemotherapy regimen as recommended by the NCCN Breast Cancer Guidelines. The preoperative chemotherapy regimens suggested by qualified oncologists were taxane-based, anthracycline-based or a combination of the two. Furthermore, for patients with HER-2 positive status, anti-HER-2 therapy (e.g., trastuzumab) was added in the treatment. This study was approved by the Ethics Committee of Guangdong Provincial People\'s Hospital. The requirement for informed consent was waived with authorization because our study had a retrospective design and did not involve any additional interventions.

Immunohistochemistry (IHC) {#s0020}
--------------------------

IHC was performed for each patient to determine the baseline estrogen receptor (ER) status, progesterone receptor (PR) status, HER-2 status, and Ki67 status. The cutoff value for ER and PR was set at 1% \[[@bb0105]\], and the cutoff value for Ki67 was 20% \[[@bb0110],[@bb0115]\]. In regard to HER-2 status, tumors with an IHC staining of 0 to 1+ were defined as HER-2 negative and 3+ as HER-2 positive. For tumors with an IHC score of 2+, ISH testing was further performed to confirm the HER-2 status. A non-amplified ISH result denotes the HER-2 status as negative, and an amplified result denotes the HER-2 status as positive.

Determination of tumor regression patterns {#s0025}
------------------------------------------

The tumor regression patterns were determined based on the final surgical specimen. The patients underwent either BCS or mastectomy after completing NAC. In either surgical procedure, the operation zone covered the area of the primary cancer. Standard pathologic analyses were performed for the assessment of the residual tumor after preoperative chemotherapy. The surgical specimens were fixed with standard formalin solution by experienced breast pathologists and processed in standard breast tissue processors, after which the specimens were cut in parallel in a continuous manner to expose the cancer tissue. For each slice, a 5 mm slide was further prepared for H&E staining. The longest diameter of the residual invasive tumor was recorded. Type 1 regression included pCR and unifocal regression. The former was defined as no residual invasive cancer remaining after NAC (ypTis allowed). The latter was designated unifocal residual cancer tissue when the area of the original cancer with the longest diameter shrank at least 30%. Type 2 regression comprised multiple residual foci, main residual disease with satellite foci, stable disease (SD) and progressive disease (PD). Multiple residual foci showed at least 2 separate foci in the continuous slides, whereas main residual disease with satellite foci showed a dominant residual disease with at least 1 minor accompanying focus. SD and PD were defined according to RECIST version 1.1 \[[@bb0120]\]. PD indicated an increase of ≥20% in the largest diameter of the tumor. SD indicated an increase of less than 20% or a decrease of less than 30% in the tumor\'s largest diameter ([Fig. 1](#f0005){ref-type="fig"}). Three breast pathologists with more than 15 years of experience interpreting breast specimens independently examined the specimens and determined the tumor regression pattern based on the H&*E*-stained slides. Agreements were made on the tumor regression patterns among the 3 pathologists to reduce possible errors caused by interobserver variability.Fig. 1Tumor regression patterns after neoadjuvant chemotherapy.a Primary cancer.b Type 1 regression (complete remission).c Type 1 regression (concentric regression).d Type 2 regression (multiple residual foci).e Type 2 regression (a main residual disease with satellite foci).f Type 2 regression (stable disease).g Type 2 regression (progressive disease).Fig. 1

ROI masking and radiomic feature extraction {#s0030}
-------------------------------------------

The patients underwent breast MRI examination within one week prior to the biopsy using a field strength magnet of 1.5 T or 3.0 T. Two imaging sequences, including diffusion-weighted imaging (DWI) and fat-suppressed T2-weighted imaging (T2WI), were acquired for each patient. T2WIs were obtained before the injection of contrast, and DWI sequences were collected at 2 b values (b = 0 and 1000 s/mm2) after the completion of dynamic contrast-enhanced imaging.

Two radiologists with 10 years of experience were responsible for tumor masking. For each MRI series, they evaluated the boundary of the tumor independently. For any disagreements, a third consulting radiologist with at least 30 years of experience determined the tumor border through discussion to decrease the interobserver variability. Tumor contours on every slice in DCE were manually delineated using ITK-SNAP ([www.itksnap.org](http://www.itksnap.org){#ir0005}), excluding vessels and hemorrhagic or necrotic foci. With the help of the calibration tool and wipe tool in ITK-SNAP, the acute masking of ROI in T2WI and DWI was assured ([Fig. 2](#f0010){ref-type="fig"}).Fig. 2Tumor masking in different MR sequences. a. DCE b. T2WI c. DWI.Fig. 2

By applying the feature extractor function of the "radiomics" package in Python (version: 3.7; [www.python.org](http://www.python.org){#ir0010}), each sequence of the MR images had 1158 multidimensional features extracted.

Feature screening and radiomic signature construction {#s0035}
-----------------------------------------------------

First, we performed Mann-Whitney *U* test screening on T2WI and ADC sequence features, retaining features with *p* values less than 0.05. Then, the elastic network chose the residual features (11 from T2WI; 229 from ADC), and the predictive features were selected. Model convergence was achieved through a five-fold cross-validation strategy. The support vector machine (SVM) is a nonlinear classifier with a radial basis function kernel. The SVM was trained based on features from PC and determined parameters by the five-fold cross-validation strategy. The radiomic signature was computed for each patient in the validation cohort via the SVM model, and ROC curves and areas under the ROC curve (AUCs) were calculated.

Feature selection was implemented by the 'radiomics' package of Python (version: 3.7; [www.python.org](http://www.python.org){#ir0015}), and radiomic signature construction was implemented by the 'sklearn' package of Python (version: 3.7; [www.python.org](http://www.python.org){#ir0020}).

Construction of the clinical and combined models {#s0040}
------------------------------------------------

The commonly used clinicopathological factors, including age, node stage, tumor stage, PR status, ER status, and neoadjuvant chemotherapy (NAC) regimen, were prepared for building a clinical prediction model. Significant characteristics were selected using backward stepwise selection, after which these filtered indicators were used to construct a clinical prediction model applying multivariate logistic regression.

Regarding the construction of the final model, based on the screened clinicopathological factors and the radiomic signature, a multivariate logistic regression model was constructed.

The ROC curves and AUC values of the clinical model and combination model were calculated to assess the predictive ability of the models.

Both the clinical and combined model were implemented by R software (version 3.6.2; <http://www.Rproject.org>) with the package 'glm2'.

Evaluations of the prediction models\' performance {#s0045}
--------------------------------------------------

ROC curve analysis is often used to assess the predictive performance of radiomic signatures and clinical and combined models. The ROC analysis was implemented through the 'pROC' package in R software (version 3.6.2; <http://www.Rproject.org>). To further compare the performance measures of the prediction models, we employed decision curve analysis (DCA) in both the primary and validation cohort. Furthermore, the net reclassification index (NRI) and the integrated discrimination improvement (IDI) between the two different models were also calculated to evaluate their performance. Finally, we presented the most predictive model as a nomogram and calibration curve analysis was employed to evaluate the nomogram.

Results {#s0050}
=======

Clinical characteristics {#s0055}
------------------------

A total of 144 patients were recruited into the study, with a median age of 49 years (range 24--73 years). Clinical features of 144 patients and their associations with regression patterns are shown in [Table 1](#t0005){ref-type="table"}. One hundred patients were included in the primary cohort (PC), and 44 were included in the validation cohort (VC). There was no significant difference in the proportion of type 2 shrinkage (17% and 18% in the PC and VC, respectively, *p* = 1) in the two cohorts and no significant difference in the type 2 shrinkage ratio of different molecular types (luminal of 20.8%, HER2 positive of 12.0%, TNBC of 8.7%, *p* = 0.327) in the cohorts.Table 1Clinical features of 144 patients and their associations with regression patterns.Table 1FactorsPrimary cohortP valueValidation cohortP valueType 1 regressionType 2 regressionType 1 regressionType 2 regressionAge (years), mean ± SD50.24±9.3347.82±8.890.34448.50±9.3249.25±13.560.709Menopausal status0.8770.524Premenopausal59 (71.1%)13 (76.5%)25 (69.4%)4 (50.0%)Postmenopausal24 (28.9%)4 (23.5%)11 (30.6%)4 (50.0%)ER status0.0140.652≤1%36 (43.4%)2 (11.8%)8 (22.2%)3 (37.5%)\>1%47 (56.6%)15 (88.2%)28 (77.8%)5 (62.5%)PR status0.0900.423≤1%38 (45.8%)4 (23.5%)10 (27.8%)4 (50.0%)\>1%45 (54.2%)13 (76.5%)26 (72.2%)4 (50.0%)HER2 status0.7970.695Positive37 (44.6%)7 (41.2%)11 (30.6%)3 (37.5%)Negative46 (55.4%)10 (58.8%)25 (69.4%)5 (62.5%)Ki67 status0.2581≤20%16(19.3%)6(35.3%)12(33.3%)3(37.5%)\>20%67(80.7%)11(64.7%)24(66.7%)5(62.5%)T stage0.3900.080T273 (88.0%)13 (76.5%)35 (97.2%)6 (75.0%)T3--410 (12.0%)4 (23.5%)1 (2.8%)2 (25.0%)N stage0.3040.053049 (59.1%)7 (41.2%)20 (55.5%)1 (12.5%)129 (34.9%)7 (41.2%)12 (33.3%)4 (50.0%)24 (4.8%)2 (11.7%)2 (5.6%)3 (37.5%)31 (1.2%)1 (5.9%)2 (5.6%)0 (0.0%)Molecular subtype0.0500.464Luminal47 (56.6%)15 (88.2%)29 (80.6%)5 (62.5%)HER2 over-expressed19 (22.9%)1 (5.9%)3 (8.3%)2 (25.0%)TNBC17 (20.5%)1 (5.9%)4 (11.1%)1 (12.5%)NAC regimen1.0000.710Anthracycline based22 (26.5%)4 (23.5%)15 (41.7%)4 (50.0%)Non-anthracycline based61 (73.5%)13 (76.5%)21 (58.3%)4 (50.0%)[^2]

Feature selection and radiomic signature construction {#s0060}
-----------------------------------------------------

Two salient features (Original_shape_Sphericity and Log-sigma-3-0-mm-3D_firstorder_MeanAbsoluteDeviation) from T2WI and ADC, respectively, were finally selected through the Mann-Whitney *U* test and elastic network to prepare for the construction of a radiomic signature.

Construction of the clinical and combined models {#s0065}
------------------------------------------------

Two significant clinicopathological indicators, namely, node stage and ER status, were selected through backward stepwise selection, after which they were incorporated into building a clinical prediction model. The selected clinical indicators and the radiomic signature were utilized to create a combined model. The relevant parameters of the clinical model and the combined prediction model are listed in [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, respectively.Table 2Details of the clinical prediction model.Table 2Intercept and variableClinical prediction modelCoefficientOdds ratio (95% CI)*p*Intercept3.5430087--3.55e-05N stage−0.78680740.45530 (0.210980-- 0.982540)0.0450ER status−1.93745030.14407 (0.028898-- 0.718270)0.0181[^3]Table 3Details of the combined prediction model.Table 3Intercept and variableCombined prediction modelCoefficientOdds ratio (95% CI)*p*Intercept4.2903--0.0003Radiomic signature1.760519.43400 (4.247300-- 88.92700)0.0001N stage−1.33150.26408 (0.086122-- 0.80978)0.0199ER status−2.15000.11648 (0.016337-- 0.83049)0.0319[^4]

Evaluations of the prediction models\' performance {#s0070}
--------------------------------------------------

In the ROC analysis, the area under the ROC curve (AUC) of the radiomic signature has reached 0.858 (95% CI: 0.7762--0.9389) in the PC and 0.819 (95% CI: 0.619--1) in the VC. The clinical prediction model yielded an AUC of 0.709 (95% CI: 0.5942--0.8239) in the PC and 0.597 (95% CI: 0.3122--0.8823) in the VC. Regarding the combined model, it achieved a performance with an AUC of 0.902 (95% CI: 0.8343--0.9701) in the PC and 0.826 (95% CI: 0.6774--0.9753) in the VC ([Fig. 3](#f0015){ref-type="fig"}). In the ROC curve analysis of the clinical and combined model, the AUC was increased by 0.193 in the PV and by 0.229 in the VC. This result shows that the predictive ability of the combined prediction model was significantly improved in both cohorts.Fig. 3ROC curves of radiomic signature, clinical prediction model and combined prediction model in both cohorts. a ROC curves in the primary cohort. b ROC curves in the validation cohort.Fig. 3

The decision curve of the three prediction models showed that the combined model could achieve the maximum net benefit, as shown in [Fig. 4](#f0020){ref-type="fig"}. We took the combined prediction model as the new model, the clinical prediction model and the radiomic signature as the old model, respectively. The NRI and IDI were 0.3877 (*p* = 0.0013) and 0.2692 (*p* \< 0.001), respectively, between the clinical model and the combined model. The NRI and the IDI between the signature and the combined model were calculated to be 0.3529 (*p* = 0.00287) and 0.1212 (*p* = 0.00887), respectively. As can be seen from the values of NRI and IDI, the new model (the combined prediction model) had improved prediction performance compared to the old model (the clinical prediction model; the radiomic signature). Therefore, the combined model is the most predictive for type 1 regression. A nomogram consisting of node stage, ER status, and the radiomic signature was created and its calibration curve illustrated good concordance between the predicted and actual outcomes of type 1 regression, as shown in [Fig. 5](#f0025){ref-type="fig"}.Fig. 4Decision curve analysis for radiomic signature, clinical prediction model and combined prediction model in both cohorts. The blue line represents the clinical prediction model. The yellow line represents the radiomic signature. The red line represents the combined prediction model. The gray line represents the assumption that all the patients appeared Type 1 tumor regression. The black line represents the assumption that no patients appeared Type 1 tumor regression.a Decision curve analysis in the primary cohort.b Decision curve analysis in the validation cohort.Fig. 4Fig. 5Nomogram, calibration curve of the nomogram in both cohorts. The red line represents the performance of the nomogram. The blue dotted line represents an ideal prediction.a Nomogram for the combined prediction model.b Calibration curve of the nomogram in the primary cohort.c Calibration curve of the nomogram in the validation cohort.Fig. 5

Discussion {#s0075}
==========

In this study, we studied the correlations between tumor regression patterns and MRI characteristics. A model combining the multiparametric MRI signature, node stage and ER status was established to predict tumor regression patterns after NAC at a very early stage. The model achieved an AUC of 0.902 in the PC and 0.826 in the VC.

Breast-conserving surgery is one of the purposes of receiving NAC. It has been clearly indicated that a clear surgical margin is the key to the success of BCS. In clinical practice, however, the recurrence rate is somewhat higher in patients receiving NAC than in those receiving chemotherapy, which can be explained by false negative margins in surgery. Ling et al. divided tumor regression patterns into 2 categories \[[@bb0030]\]. Patients with pCR and unifocal residual disease after NAC had a higher rate of 4-year IBTR-free survival than those with multifocal disease. Based on clinical interest, we categorized tumor regression patterns into 2 types as well. Patients with type 2 regression show an inadequate response to the planned preoperative therapy, with either satellite foci remaining or no significant decline in tumor size. Our combined model serves to predict tumor regression at baseline, offers surgical options to surgeons and patients, and provides guidance on the early modification of therapeutic treatment.

To the best of our knowledge, our study is the first to predict breast tumor regression patterns using MR radiomics. MR examinations both at baseline and post-NAC are clinical routines in our center; hence, the MRI data were easily accessible, and no invasive procedure was needed in our study. A radiomic signature combining DWI and T2WI features was first established in our study. DWI and T2WI have been used to evaluate the tumor response to chemotherapy \[[@bb0095],[@bb0125]\]. One MRI feature from each series was extracted to create the radiomic signature. The AUCs of the radiomic signature in the PC and VC were 0.858 and 0.819, respectively, which are both acceptable and satisfactory. Two clinicopathological factors, including node stage and ER status, were found to be closely related to tumor regression patterns. Therefore, these factors were incorporated into the combined model, and the NRI and IDI illustrated the superiority of the combined model over the radiomic signature and the clinical prediction model. A nomogram was established to predict type 1 regression by incorporating two clinical factors and the radiomic signature. The calibration curve and decision curve demonstrated that the model had a good fit to actual observations and had net clinical benefit.

Consistent with the findings of previous literature \[[@bb0130],[@bb0135]\], tumors with later nodal stages and higher ER expression levels are less likely to have type 1 regression. In other words, these patients may not be BCS candidates. Researchers have focused on correlating molecular subtypes with tumor regression types, but no consensus has been reached \[[@bb0140],[@bb0145]\]. Among 144 patients recruited in this study, the percentages of type 2 regression in luminal breast cancers, HER2-overexpressing breast cancers and TNBCs were 20.8%, 12.0%, and 8.7%, respectively (*p* = 0.254). HER2-overexpressing breast cancers and TNBCs had a lower rate of type 2 regression, which could be explained by the addition of HER2-targeted therapy in the former and the more invasive nature of the latter.

There are still some limitations in our study. First, the data distribution was imbalanced between the 2 cohorts. Tumors showing type 2 regression are encountered less frequently, which is consistent with clinical observation. Most tumors have good responses to preoperative chemotherapy (and anti-HER2 therapy, e.g., trastuzumab), which leads to pCR or unifocal residual disease after NAC. Second, due to the retrospective nature of our study, only accessible clinical factors could be taken into consideration. The exploration of the correlations between tumor regression and other variables, e.g., a gene signature or an immune signature, is worthwhile. Finally, we did not consider the molecular subtypes separately. The analysis of tumor regression in luminal-type breast cancer would be meaningful.

Conclusions {#s0080}
===========

Our study established a unique model combining a radiomic signature and clinicopathological factors to predict tumor regression patterns prior to the initiation of NAC. The early prediction of type 2 regression offers the opportunity to modify preoperative treatments or aids in determining surgical options.
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